Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06158516
PHASE2

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Sponsor: Changhai Hospital

View on ClinicalTrials.gov

Summary

pNENs still have a risk of recurrence after radical resection, and the overall recurrence and metastasis rate is as high as 13.7%-36.2% in China. At present, there is no standard adjuvant therapy for pNEN, and prospective studies are still lacking. This study was a randomized, double-blind, placebo-controlled, multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET, in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy.

Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2023-11-30

Completion Date

2026-11-29

Last Updated

2023-12-06

Healthy Volunteers

No

Interventions

DRUG

Surufatinib

Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle

DRUG

Placebo

Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle

Locations (1)

Changhai Hospital

Shanghai, China